etoposide has been researched along with Macrophage Activation Syndrome in 18 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (5.56) | 29.6817 |
| 2010's | 8 (44.44) | 24.3611 |
| 2020's | 9 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| He, L; Jin, Z; Liu, M; Wang, Y; Wang, Z; Zhang, R | 1 |
| Bao, CD; Chen, S; Fu, Q; Li, T; Lv, L; Wang, R; Wang, X; Ye, S | 1 |
| Béné, MC; Chevallier, P; Eveillard, M; Garnier, A; Guillaume, T; Jullien, M; Le Bourgeois, A; Peterlin, P; Seguin, A | 1 |
| He, L; Hua, Z; Liu, M; Wang, Y; Wang, Z; Yao, S; Zhang, R; Zou, H | 1 |
| Jesudas, R; Nichols, KE | 1 |
| Bailly, C | 1 |
| Diack, ND; Diagne, N; Dieng, M; Djiba, B; Faye, A; Kane, BS; Ndao, AC; Ndongo, S; Niasse, M; Pouye, A; Sow, M | 1 |
| Maeda, S; Naniwa, T; Ohmura, SI; Tamechika, S; Uehara, K; Yamabe, T | 1 |
| Kanegane, H; Kong, P; Tang, X; Yan, X; Yang, X; Yao, H; Zhang, X; Zhang, Z; Zhao, Q; Zhao, X | 1 |
| Andersson, U; Erlandsson Harris, H; Henter, JI; Horne, AC; Palmblad, K; Schierbeck, H; Sundberg, E | 1 |
| Báez, M; Borjas-Aguilar, KL; García-Pavón, S; Murata, C; Yamazaki-Nakashimada, MA | 1 |
| Junga, Z; Keith, M; Stitt, R; Tracy, C | 1 |
| Komagata, Y | 1 |
| Alessio, M; Anton, J; Avcin, T; Bovis, F; Chasnyk, V; Cron, RQ; Davì, S; Demirkaya, E; Espada, G; Fischbach, M; Frosch, M; Gao, YJ; Grom, A; Horne, A; Huasong, Z; Huber, A; Insalaco, A; Jelusic, M; Kasapcopur, O; Khubchandani, R; Kitoh, T; Lehmberg, K; Li, C; Maritsi, D; Martini, A; Merino, R; Miettunen, P; Minoia, F; Ozen, S; Pal, P; Ravelli, A; Ruperto, N; Russo, R; Sanner, H; Sawhney, S; Shakoory, B; Shenoi, S; Uziel, Y; Weitzman, S; Wouters, C | 1 |
| Andersson, U; Antoine, DJ; Harris, HE; Henter, JI; Horne, AC; Palmblad, K; Schierbeck, H; Sundberg, E | 1 |
| Jin, J | 1 |
| Abdelhaleem, M; Benseler, S; Gupta, AA; Tyrrell, P; Valani, R; Weitzman, S | 1 |
| Bayrakci, B; Carcillo, JA; Citak, A; Demirkol, D; Dursun, O; Erkek, N; Gedik, H; Karabocuoglu, M; Karapinar, B; Kendirli, T; Kesici, S; Koroglu, TF; Yildizdas, D | 1 |
4 review(s) available for etoposide and Macrophage Activation Syndrome
| Article | Year |
|---|---|
Recent advances in the treatment of hemophagocytic lymphohistiocytosis and macrophage activation syndrome.
Topics: Cytokines; Etoposide; Humans; Interferon-gamma; Interleukin-1; Lymphohistiocytosis, Hemophagocytic; Macrophage Activation Syndrome | 2022 |
Etoposide: A rider on the cytokine storm.
Topics: Cytokine Release Syndrome; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Lymphohistiocytosis, Hemophagocytic; Macrophage Activation Syndrome; Transplantation, Autologous | 2023 |
Kawasaki Disease Complicated With Macrophage Activation Syndrome: A Systematic Review.
Topics: Adolescent; Adrenal Cortex Hormones; Antibodies, Monoclonal; Aspartate Aminotransferases; Child; Child, Preschool; Coronary Vessel Anomalies; Cyclosporine; Etoposide; Female; Fever; Humans; Infant; Macrophage Activation Syndrome; Male; Mucocutaneous Lymph Node Syndrome; Tumor Necrosis Factor-alpha | 2017 |
[Serious organ damage and intractable clinical conditions in rheumatic and connective tissue disease--progress in pathophysiology and treatment. Topics: II. Clinical conditions special attention needed to be paid to; 4. Macrophage activating syndrome and
Topics: Antirheumatic Agents; Connective Tissue Diseases; Cyclosporine; Dexamethasone; Drug Therapy, Combination; Etoposide; gamma-Globins; Humans; Immunosuppressive Agents; Lymphohistiocytosis, Hemophagocytic; Macrophage Activation Syndrome; Methotrexate; Methylprednisolone; Pulse Therapy, Drug | 2013 |
14 other study(ies) available for etoposide and Macrophage Activation Syndrome
| Article | Year |
|---|---|
Effectiveness of a modified doxorubicin-etoposide-methylprednisolone regimen for the treatment of refractory or relapsed macrophage activation syndrome in adults.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Etoposide; Humans; Macrophage Activation Syndrome; Methylprednisolone; Salvage Therapy | 2022 |
Short-term, low-dose etoposide in refractory adult-onset Still's disease-associated macrophage activation syndrome.
Topics: Adult; Etoposide; Humans; Lymphohistiocytosis, Hemophagocytic; Macrophage Activation Syndrome; Prognosis; Still's Disease, Adult-Onset | 2022 |
Dramatic Recovery after Etoposide Phosphate Infusion for Hemophagocytic Lymphohistiocytosis/Macrophage Activation Syndrome following Treatment with Tisagenlecleucel in a Young Patient with Relapsed Acute Lymphoblastic Leukemia: A Case Report.
Topics: Acute Disease; Etoposide; Humans; Lymphohistiocytosis, Hemophagocytic; Macrophage Activation Syndrome; Organophosphorus Compounds; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Receptors, Antigen, T-Cell | 2022 |
Macrophage activation syndrome in adults: Characteristics, outcomes, and therapeutic effectiveness of etoposide-based regimen.
Topics: Adult; Autoimmune Diseases; Chemokine CXCL10; Chemokine CXCL12; Etoposide; Glucocorticoids; Humans; Interleukin 1 Receptor Antagonist Protein; Interleukin-10; Interleukin-18; Interleukin-7; Lymphohistiocytosis, Hemophagocytic; Macrophage Activation Syndrome; Retrospective Studies; Tumor Necrosis Factor-alpha | 2022 |
Macrophage activation syndrome, a rare complication of primary Sjögren's syndrome: a case report.
Topics: Adult; Africa South of the Sahara; Antineoplastic Agents, Phytogenic; Etoposide; Female; Ferritins; Fever; Humans; Hypertriglyceridemia; Macrophage Activation Syndrome; Phagocytosis; Sjogren's Syndrome | 2019 |
Successful use of short-term add-on tocilizumab for refractory adult-onset still's disease with macrophage activation syndrome despite treatment with high-dose glucocorticoids, cyclosporine, and etoposide.
Topics: Antibodies, Monoclonal, Humanized; Cyclosporine; Drug Resistance; Drug Therapy, Combination; Etoposide; Glucocorticoids; Humans; Immunosuppressive Agents; Macrophage Activation Syndrome; Molecular Targeted Therapy; Severity of Illness Index; Still's Disease, Adult-Onset; Treatment Outcome | 2020 |
UNC13D mutation in a patient with juvenile polymyositis with recurrent macrophage activation syndrome.
Topics: Adolescent; Antirheumatic Agents; Autoantibodies; Bone Marrow Examination; Cyclosporine; Etoposide; Homozygote; Humans; Macrophage Activation Syndrome; Male; Membrane Proteins; Methylprednisolone; Mutation, Missense; Patient Care Planning; Polymyositis; Positron Emission Tomography Computed Tomography; Remission Induction; Topoisomerase II Inhibitors; Treatment Outcome | 2021 |
Therapeutic administration of etoposide coincides with reduced systemic HMGB1 levels in macrophage activation syndrome.
Topics: Adolescent; Antineoplastic Agents, Phytogenic; Biomarkers; Child; Child, Preschool; Cytokines; Etoposide; Female; HMGB1 Protein; Humans; Immunosuppressive Agents; Inflammation Mediators; Macrophage Activation Syndrome; Male; Treatment Outcome | 2021 |
Novel use of rituximab in macrophage activation syndrome secondary to systemic lupus erythematosus.
Topics: Antineoplastic Agents, Immunological; Antirheumatic Agents; Diagnosis, Differential; Etoposide; Female; Humans; Hydroxychloroquine; Infusions, Intravenous; Lupus Erythematosus, Systemic; Macrophage Activation Syndrome; Rare Diseases; Rituximab; Treatment Outcome; Young Adult | 2017 |
Clinical features, treatment, and outcome of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a multinational, multicenter study of 362 patients.
Topics: Adrenal Cortex Hormones; Arthritis, Juvenile; Biological Products; Child; Child, Preschool; Cohort Studies; Cyclosporine; Etoposide; Female; Fever; Hepatomegaly; Humans; Intensive Care Units; International Cooperation; Macrophage Activation Syndrome; Male; Prevalence; Retrospective Studies; Splenomegaly; Survival Rate; Treatment Outcome | 2014 |
High systemic levels of the cytokine-inducing HMGB1 isoform secreted in severe macrophage activation syndrome.
Topics: Adolescent; Biomarkers; Child; Child, Preschool; Cytokines; Etoposide; Female; Ferritins; HMGB1 Protein; Humans; Macrophage Activation Syndrome; Male; Protein Isoforms | 2015 |
A continuous infusion of etoposide and doxorubicin for refractory MAS management.
Topics: Doxorubicin; Etoposide; Female; Glucocorticoids; Humans; Immunoglobulins, Intravenous; Immunologic Factors; Infusions, Intravenous; Macrophage Activation Syndrome; Methylprednisolone; Still's Disease, Adult-Onset; Topoisomerase II Inhibitors; Young Adult | 2016 |
Experience with hemophagocytic lymphohistiocytosis/macrophage activation syndrome at a single institution.
Topics: Adolescent; Adrenal Cortex Hormones; Cause of Death; Child; Child, Preschool; Cyclosporine; Etoposide; Female; Hematologic Neoplasms; Humans; Immunoglobulins, Intravenous; Infant; Lymphohistiocytosis, Hemophagocytic; Macrophage Activation Syndrome; Male; Retrospective Studies; Rheumatic Diseases; Steroids; Virus Diseases | 2009 |
Hyperferritinemia in the critically ill child with secondary hemophagocytic lymphohistiocytosis/sepsis/multiple organ dysfunction syndrome/macrophage activation syndrome: what is the treatment?
Topics: Adolescent; Antineoplastic Agents, Phytogenic; Child; Child, Preschool; Combined Modality Therapy; Critical Illness; Cyclosporine; Dexamethasone; Etoposide; Female; Ferritins; Glucocorticoids; Humans; Immunoglobulins, Intravenous; Immunosuppressive Agents; Iron Overload; Lymphohistiocytosis, Hemophagocytic; Macrophage Activation Syndrome; Male; Multiple Organ Failure; Plasma Exchange; Prednisolone; Regression Analysis; Sepsis; Survival Rate; Treatment Outcome; Turkey | 2012 |